Patents by Inventor Edward R. DAMIANO

Edward R. DAMIANO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220080119
    Abstract: Systems and methods are disclosed herein for monitoring the status of an ambulatory medical device and the health condition of a subject that receives therapy from the ambulatory medical device. The ambulatory medical device can have a touchscreen display user interface to receive input signals from a user and display alarm conditions associated with the status of an ambulatory medical device or health condition of a subject. The disclosed methods and systems can determine whether status information received from a monitoring system interface satisfies an alarm condition for the ambulatory medicament device or for the subject. If the status information satisfies an alarm condition, the touchscreen user interface can display one or more alarm status indicators corresponding to the alarm condition. The user can activate a therapy change interface on the touchscreen display and modify a control parameter of the ambulatory medical device that controls the therapy delivery to the subject.
    Type: Application
    Filed: September 27, 2021
    Publication date: March 17, 2022
    Inventors: Michael J. Rosinko, Edward R. Damiano, David Chi-Wai Lim, Firas H. El-Khatib, Justin P. Brown, Bryan Dale Knodel, Himanshu Patel
  • Publication number: 20220072227
    Abstract: Systems and methods are disclosed herein for switching an application executing on an ambulatory medical device to a new application without interrupting therapy provided by the ambulatory medical device to a subject. The ambulatory medical device may receive an indication that an update to an application executing on the ambulatory insulin pump is available, establish a communication connection to a host computing system, download and install the application update, while a prior version of the application continues to run. The disclosed systems and methods can confirm successful installation of the application update on the ambulatory medical device and switch control of the ambulatory medical device from the prior version to the new version of the application without interrupting therapy provided to the subject.
    Type: Application
    Filed: September 17, 2021
    Publication date: March 10, 2022
    Inventors: Himanshu Patel, Michael J. Rosinko, Edward R. Damiano, David Chi-Wai Lim, Firas H. El-Khatib, John R. Costik, Justin P. Brown, Bryan Dale Knodel
  • Publication number: 20220072228
    Abstract: Systems and methods are disclosed herein for switching control of an ambulatory medical device from an application executing on the ambulatory medical device to a safe version or a new version of the application without interrupting therapy provided by the ambulatory medical device to a subject. The ambulatory medical device can maintain copies of a safe version and a new version of the application. The disclosed systems and methods can execute the new version, while the prior version of the application continues to execute, determine whether a minimum set of operating conditions are satisfied by the new version, and switch control of the ambulatory medical device from the prior version to the new version. The systems and methods can also automatically revert to the safe version of the application case the current version is malfunctioning without interrupting therapy provided to the subject.
    Type: Application
    Filed: September 17, 2021
    Publication date: March 10, 2022
    Inventors: Michael J. Rosinko, Edward R. Damiano, David Chi-Wai Lim, Firas H. El-Khatib, Himanshu Patel, John R. Costik, Justin P. Brown, Bryan Dale Knodel
  • Publication number: 20220062547
    Abstract: A blood glucose control system can generate an indication of total carbohydrate therapy over a period during use by a subject. The system can be connected to a medicament pump configured to deliver insulin therapy, other types of medicament therapy, or a combination of medicament therapies to the subject. The system can determine an amount of a counter-regulatory agent to respond to an impending risk of hypoglycemia or an episode of hypoglycemia and determine a dose of carbohydrate therapy based at least in part on the amount of the counter-regulatory agent. The system can track determined doses of carbohydrate therapy to generate the indication of total carbohydrate therapy over the period.
    Type: Application
    Filed: June 16, 2021
    Publication date: March 3, 2022
    Inventors: Firas H. El-Khatib, Edward R. Damiano
  • Patent number: 11260174
    Abstract: Systems and methods presented herein relate to managing ambulatory medical device data access. A computing system of a networked computing environment can establish a direct end-to-end data connection to an ambulatory medical device via a wireless wide area network. A public key of the computing system may be transmitted to the ambulatory medical device permitting the ambulatory medical device to encrypt data to be transmitted to the computing system. The computing system may receive, via the direct end-to-end data connection, encrypted data from the ambulatory medical device, and upon decrypting the data can generate a therapy report based at least in part on the therapy data. This therapy report may include time-series therapy data relating to the therapy delivered by the ambulatory medical device over a particular time period. The computing system can restrict access to the therapy report to authorized users.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: March 1, 2022
    Assignee: Beta Bionics, Inc.
    Inventors: Himanshu Patel, Edward R. Damiano, Firas H. El-Khatib, Michael J. Rosinko
  • Publication number: 20220054746
    Abstract: Systems and methods presented herein relate to a method of sharing therapy data of an ambulatory medical device with a computing system of a networked computing environment. The computing system may be identified using an authorized system list that includes an address of approved computing systems. Using an address of an approved computing system, a direct end-to-end data connection may be established via a wireless wide area network. A public key of the computing system may be received permitting the ambulatory medical device to encrypt data to be transmitted to the computing system. The ambulatory medical device can transmit the encrypted therapy data to the computing system over the direct end-to-end data connection.
    Type: Application
    Filed: June 29, 2021
    Publication date: February 24, 2022
    Inventors: Himanshu Patel, Edward R. Damiano, Firas H. El-Khatib, Michael J. Rosinko
  • Publication number: 20210402090
    Abstract: A blood glucose control system is configured to modify therapy provide to a subject and determine whether the modified therapy results in a statistically significant improvement in glycemic control. The system obtains glycemic control information resulting from delivery of first therapy using a first value of a control parameter and determines a first effect corresponding to the first therapy. The control parameter is set to a second value that differs from the first value. The system obtains glycemic control information resulting from the delivery of the second therapy using the second value of the control parameter and determines a second effect corresponding to the second therapy. The system can perform a comparative assessment and determine whether the second value for the control parameter results in a statistically significant improvement in glycemic control for the subject.
    Type: Application
    Filed: March 5, 2021
    Publication date: December 30, 2021
    Inventors: Edward R. Damiano, Firas H. El-Khatib
  • Patent number: 11154656
    Abstract: An automated blood glucose control system can provide automatic delivery of glucose control therapy to a subject and receive information about manual glucose control therapy provided to the subject. The automated blood glucose control system can indicate an amount of a bolus of medicament via a control algorithm configured to control blood glucose level in the subject. The automated blood glucose control system can indicate an amount of a manual bolus of medicament, which can be used to model a diminishment of the medicament in the subject over time based at least in part on the manual bolus of medicament.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: October 26, 2021
    Assignee: Beta Bionics, Inc.
    Inventors: Firas H. El-Khatib, Edward R. Damiano, Edward B. Raskin, David Chi-Wai Lim, Michael J. Rosinko, John R. Costik
  • Patent number: 11135363
    Abstract: Systems and methods relate to an ambulatory medicament device that can generate a dose control signal to cause a medicament pump to infuse medicament into a subject. The system can analyze status to determine whether an alarm condition for the ambulatory medicament device or for a subject is already present in a list of pending alarm conditions. If the alarm is not present, the system can determine a severity level of the alarm condition from among a plurality of severity levels and annunciate the alarm condition using one or more annunciation patterns selected based on the severity level of the alarm condition for the medicament device or for the subject. The system may maintain an indication of the alarm condition on the list of pending alarm conditions until the alarm condition is resolved.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: October 5, 2021
    Assignee: Beta Bionics, Inc.
    Inventors: Michael J. Rosinko, David Chi-Wai Lim, Edward R. Damiano, Firas H. El-Khatib, Himanshu Patel
  • Patent number: 11135366
    Abstract: An ambulatory medical device can detect a device condition and determine if the device condition satisfies a set of normal operating parameters. If the normal operating parameters are not satisfied, the ambulatory medical device can determine if the device condition stratifies a set of minimum operating parameters. If the minimum operating parameters are satisfied, the ambulatory medical device can maintain a delivery of therapy to a subject and generate an alert based on the device condition.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: October 5, 2021
    Assignee: Beta Bionics, Inc.
    Inventors: Michael J. Rosinko, Himanshu Patel, Edward R. Damiano, Firas H. El-Khatib, David Chi-Wai Lim
  • Patent number: 11135364
    Abstract: Systems and methods are disclosed herein for monitoring the status of an ambulatory medical device and the health condition of a subject that receives therapy from the ambulatory medical device. The ambulatory medical device can have a touchscreen display user interface to receive input signals from a user and display alarm conditions associated with the status of an ambulatory medical device or health condition of a subject. The disclosed methods and systems can determine whether status information received from a monitoring system interface satisfies an alarm condition for the ambulatory medicament device or for the subject. If the status information satisfies an alarm condition, the touchscreen user interface can display one or more alarm status indicators corresponding to the alarm condition. The user can activate a therapy change interface on the touchscreen display and modify a control parameter of the ambulatory medical device that controls the therapy delivery to the subject.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: October 5, 2021
    Assignee: Beta Bionics, Inc.
    Inventors: Michael J. Rosinko, Edward R. Damiano, David Chi-Wai Lim, Firas H. El-Khatib, Justin P. Brown, Bryan Dale Knodel
  • Patent number: 11135365
    Abstract: An ambulatory medicament device can generate a dose control signal for delivery of medicament to a subject and secure at least some functionality of a user interface of the ambulatory medicament device. The ambulatory medicament device can have a locked state that restricts modification of at least one control parameter. The ambulatory medicament device can have an unlocked state that allows modification of at least one control parameter. The ambulatory medicament device can accept a user input of a security code that is validated against a passcode to enter from the locked state to the unlocked state.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: October 5, 2021
    Assignee: Beta Bionics, Inc.
    Inventors: Michael J. Rosinko, Himanshu Patel, Edward R. Damiano, Firas H. El-Khatib
  • Publication number: 20210299352
    Abstract: A blood glucose control system is configured to modify therapy provided to a subject. The system can cause first therapy to be delivered by the blood glucose control system to a subject during a first therapy period. The first therapy can be delivered based at least in part on a first value of a control parameter used by a control algorithm to generate a dose control signal. The system can determine a first effect corresponding at least in part to the first therapy and autonomously generate a second value of the control parameter. The system can cause second therapy to be delivered by the blood glucose control system to the subject during a second therapy period, wherein the second therapy is delivered based at least in part on the second value of the control parameter.
    Type: Application
    Filed: March 26, 2021
    Publication date: September 30, 2021
    Inventors: Firas H. El-Khatib, Edward R. Damiano
  • Patent number: 11129938
    Abstract: Systems and methods are disclosed herein for updating an application controlling an ambulatory medical device such that application updates can be identified, downloaded and installed without interrupting therapy provided by the ambulatory medical device to a subject. The ambulatory medical device may receive an indication that an update to an application executing on the ambulatory insulin pump is available, establish a communication connection to a host computing system configured to host the application update, and download the application update. The disclosed systems and methods can determine an execution time of an installation and install the downloaded application update without interrupting therapy provided by the ambulatory medical device to the subject.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: September 28, 2021
    Assignee: Beta Bionics, Inc.
    Inventors: Michael J. Rosinko, Edward R. Damiano, David Chi-Wai Lim, Firas H. El-Khatib, Himanshu Patel, John R. Costik, Justin P. Brown, Bryan Dale Knodel
  • Patent number: 11123485
    Abstract: Systems and methods are disclosed herein for switching an application executing on an ambulatory medical device to a new application without interrupting therapy provided by the ambulatory medical device to a subject. The ambulatory medical device may receive an indication that an update to an application executing on the ambulatory insulin pump is available, establish a communication connection to a host computing system, download and install the application update, while a prior version of the application continues to run. The disclosed systems and methods can confirm successful installation of the application update on the ambulatory medical device and switch control of the ambulatory medical device from the prior version to the new version of the application without interrupting therapy provided to the subject.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: September 21, 2021
    Assignee: Beta Bionics, Inc.
    Inventors: Himanshu Patel, Michael J. Rosinko, Edward R. Damiano, David Chi-Wai Lim, Firas H. El-Khatib, John R. Costik, Justin P. Brown, Bryan Dale Knodel
  • Patent number: 11123486
    Abstract: Systems and methods are disclosed herein for switching control of an ambulatory medical device from an application executing on the ambulatory medical device to a safe version or a new version of the application without interrupting therapy provided by the ambulatory medical device to a subject. The ambulatory medical device can maintain copies of a safe version and a new version of the application. The disclosed systems and methods can execute the new version, while the prior version of the application continues to execute, determine whether a minimum set of operating conditions are satisfied by the new version, and switch control of the ambulatory medical device from the prior version to the new version. The systems and methods can also automatically revert to the safe version of the application case the current version is malfunctioning without interrupting therapy provided to the subject.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: September 21, 2021
    Assignee: Beta Bionics, Inc.
    Inventors: Michael J. Rosinko, Edward R. Damiano, David Chi-Wai Lim, Firas H. El-Khatib, Himanshu Patel, John R. Costik, Justin P. Brown, Bryan Dale Knodel
  • Publication number: 20210283328
    Abstract: Certain embodiments provide multi-medicament infusion systems for preventing the cross-channeling of medicaments. The system may include one or more of an infusion pump, medicament cartridges, cartridge connectors, a multi-channel fluid conduit, and an infusion set. The infusion pump can have an inductively chargeable battery assembly that can be charged by an inductive charging pad.
    Type: Application
    Filed: March 10, 2020
    Publication date: September 16, 2021
    Inventors: Edward R. Damiano, Firas H. El-Khatib, Mike Rosinko, Rajendranath Setty, David Henderson, Justin Brown, David Lim, Stuart Sundem, Mads Dall, Bryan Knodel
  • Publication number: 20210283332
    Abstract: A controller in a system for automatic control of blood glucose level of a subject is operative to generate an insulin dose control signal for controlling insulin delivery by a delivery device, based on time-varying glucose levels of the subject as represented by an actual glucose level signal over time. The controller operates at a regular frequency to generate the insulin dose control signal to regulate the glucose levels in the subject and employs a control algorithm that functions in conjunction with and accounting for user-determined doses, such as meal doses, whose values are entered into the controller and delivered on command of a user.
    Type: Application
    Filed: March 10, 2021
    Publication date: September 16, 2021
    Inventors: Edward R. Damiano, Firas H. El-Khatib, David Lim, Mike Rosinko
  • Patent number: 11116902
    Abstract: A blood glucose control system is configured to modify therapy provided to a subject. The system can cause first therapy to be delivered by the blood glucose control system to a subject during a first therapy period. The first therapy can be delivered based at least in part on a first value of a control parameter used by a control algorithm to generate a dose control signal. The system can determine a first effect corresponding at least in part to the first therapy and autonomously generate a second value of the control parameter. The system can cause second therapy to be delivered by the blood glucose control system to the subject during a second therapy period, wherein the second therapy is delivered based at least in part on the second value of the control parameter.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: September 14, 2021
    Assignee: Beta Bionics, Inc.
    Inventors: Firas H. El-Khatib, Edward R. Damiano
  • Patent number: 11103638
    Abstract: Systems and methods presented herein relate to cancelling a modification of medicament delivery initiated by a user. A display of a therapy control element can be generated on an interface, such as a touchscreen. The therapy control element permits a user to modify a control parameter used in a control algorithm for generating a dose control signal for delivering medicament to a subject. Responsive to receiving the modification, the control parameter may be modified at a first time from a first setting to a second setting based on an indication of the modification to the therapy control element. Responsive to receiving a restore gesture on the touchscreen at a second time, the control parameter may be restored back to the first setting. This restore gesture may be a swipe gesture performed by a user.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: August 31, 2021
    Assignee: BETA BIONICS, INC.
    Inventors: Michael J. Rosinko, Edward R. Damiano, David Chi-Wai Lim, Firas H. El-Khatib, Justin P. Brown, Bryan Dale Knodel